The risk of side effects increases if metadone is taken simultaneously with antidepressants (such as citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, amitriptyline, clomipramine, imipramine, nortriptyline). Consult your doctor if you experience symptoms such as:
If you are unsure if any of the above points apply to you, consult your doctor or pharmacist before taking Eptadone.
Use of Eptadone with food, drinks, and alcohol
Do not drink alcohol while taking this medication. Alcohol may increase the side effects of metadone. Do not drink grapefruit juice while taking this medication. Grapefruit juice may alter the effect of metadone.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy:
Breastfeeding:
Driving and operating machinery:
Eptadone contains:
The dosage must be individualized, so your doctor will establish the appropriate dose for you and make any necessary adjustments.
If you estimate that the action of Eptadone is too strong or too weak, inform your doctor or pharmacist.
For substance dependence
For intense pain
If you take more Eptadone than you should
In case of overdose or accidental ingestion, consult the Toxicological Information Service, phone 915 620 420, indicating the medication and the amount taken.
The following effects may appear:
In extreme cases, your breathing or blood circulation may stop, and you may have a heart attack.
It may cause a low level of blood sugar.
If you forgot to take Eptadone
If you forget a dose, do not take the medication when you remember.
Wait until it's time for the next dose and take only one dose.
Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Eptadone
Do not stop taking Eptadone without consulting your doctor first
You may experience side effects. If you need to stop taking Eptadone, your doctor will make you stop gradually.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
The following criterion has been used to classify the frequency of adverse reactions:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data))
The following side effects may occur with this medicine:
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
You may notice that some side effects decrease in intensity over time.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep the bottle in the outer packaging.
Medications should not be disposed of through drains or trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition of Eptadone
Appearance of the product and contents of the packaging:
Eptadone 20 mg oral solution is a transparent lemon-flavored liquid that is presented in a single-dose 20 ml bottle for oral administration only.
Each bottle contains 20 mg of methadone hydrochloride.
Holder of the marketing authorization and responsible for manufacturing:
L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A.
SS67 Fraz. Granatieri
50018 Scandicci (Florence)
Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Laboratorios Gebro Pharma, S.A.
Avenida Tibidabo nº 29
08022 Barcelona
Tel.: 93 205 86 86
Date of the last review of this leaflet:
May 2023
Other sources of information
The detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es/)
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.